Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

Abstract

AIM:

We aimed to investigate the prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy and determine which of the two was a better predictor of prognosis.

MATERIALS & METHODS:

We conducted multivariate Cox regression analysis to assess the independent effects of the NLR and PLR on patient survival.

RESULTS:

In multivariate Cox regression analysis, the NLR was an independent risk factor predicting poor prognostic factor (HR: 2.464; 95% CI: 1.305-4.652; p = 0.005) and overall survival (HR: 1.954; 95% CI: 1.172-3.257; p = 0.01); however, the PLR was not a prognostic factor (progression-free survival; p = 0.105; overall survival; p = 0.239).

CONCLUSION:

The NLR was a better prognostic indicator than the PLR for advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

• Authors: Dong Guo, Minghuan Li, Dawei Chen, Wang Jing, Hui Zhu, Lei Fu, Li Kong, Jinbo Yue, Jinming Yu
• Journal: Future oncology (London, England) (Future Oncol) Vol. 15 Issue 6 Pg. 625-635 (Feb 2019) ISSN: 1744-8301 [Electronic] England
• PMID: 30430864 (Publication Type: Journal Article)

Chemical References

• Biomarkers
• Platinum

Topics

• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Biomarkers
• Blood Platelets
• Carcinoma, Non-Small-Cell Lung (blood, drug therapy, mortality, pathology)
• Female
• Humans
• Kaplan-Meier Estimate
• Leukocyte Count
• Lung Neoplasms (blood, drug therapy, mortality, pathology)
• Lymphocytes
• Male
• Middle Aged
• Neoplasm Staging
• Neutrophils
• Platelet Count
• Platinum (administration & dosage)
• Prognosis
• ROC Curve
• Treatment Outcome